Ftd Als Spectrum Disorder is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Amyotrophic lateral sclerosis (ALS) and Frontotemporal Dementia (FTD) are now recognized as representing the extremes of a single clinical, pathological, and genetic continuum rather than two separate diseases. This spectrum is formally termed the ALS-Frontotemporal Spectrum Disorder (ALS-FTSD), codified in the revised Strong et al. 2017 consensus criteria.1
The concept of a continuum is supported by three pillars of convergence: (1) clinical overlap — motor neuron dysfunction and frontotemporal cognitive/behavioral dysfunction frequently co-occur; (2) genetic overlap — the same gene mutations (most notably C9orf72) cause both ALS and FTD, often within the same family; and (3) pathological overlap — TDP-43 Proteinopathy is the defining molecular signature of both conditions (found in ~97% of ALS and ~50% of FTLD cases).2
The behavioral variant FTD (bvFTD) is the most common FTD subtype to co-occur with ALS, though language variants (semantic dementia and nonfluent PPA) can also overlap.
The 2017 consensus criteria formally established the ALS-FTSD diagnostic framework with the following categories:1
| Category | Definition |
|---|---|
| ALS-FTD | Full Motor Neuron Disease + behavioral/cognitive impairment meeting FTD criteria. Requires ≥3 Rascovsky criteria symptoms, OR ≥2 symptoms with loss of insight, OR language impairment meeting PPA criteria |
| ALSci | ALS with cognitive impairment — executive dysfunction (impaired verbal fluency or ≥2 executive function measures) without meeting full FTD criteria |
| ALSbi | ALS with behavioral impairment — apathy ± other behavioral change, or ≥2 supportive Rascovsky criteria features without meeting full FTD criteria |
| ALScbi | ALS with combined cognitive and behavioral impairment — both ALSci and ALSbi criteria met (introduced in 2017 revision) |
In ALS-FTD, frontotemporal symptoms often appear first, including personality changes, behavioral disinhibition, apathy, loss of empathy, compulsive behaviors, [hyperorality], and executive dysfunction. Motor symptoms may follow weeks to years later. Conversely, ALS patients may present first with motor symptoms and subsequently develop progressive cognitive/behavioral changes.
Gene-specific behavioral profiles have been identified:6
The C9orf72 GGGGCC hexanucleotide repeat expansion is the most common genetic cause of both familial ALS and familial FTD. It was discovered simultaneously by two groups in 2011:78
Three disease mechanisms (non-mutually exclusive):
Penetrance and variability: Near-complete penetrance (~99.5%) by age 83, but approximately 50% penetrance by age 58. Marked intrafamilial variability — the same mutation can produce pure ALS, pure FTD, ALS-FTD, or psychiatric phenotypes within a single family.9
Multiple genes are mutated in both ALS and FTD, implicating shared pathways of autophagy, RNA processing, [protein quality control], and the ubiquitin-proteasome system:
| Gene | Protein | Pathway | Notes |
|---|---|---|---|
| C9orf72 | C9orf72 | autophagy, vesicle trafficking | Most common genetic cause of familial ALS and FTD |
| TARDBP | TDP-43 | RNA processing | Encodes TDP-43; mutations cause ALS and rare FTD |
| FUS | FUS/TLS | RNA processing | Mutations cause ALS (especially juvenile) and rare FTLD-FUS |
| TBK1 | TANK-binding kinase 1 | Autophagy, innate immunity | Phosphorylates optineurin and p62 |
| VCP | Valosin-containing protein | ER-associated degradation | Also causes inclusion body myopathy and Paget disease |
| SQSTM1 | p62/Sequestosome-1 | Selective autophagy | Interacts with TBK1 and optineurin |
| UBQLN2 | Ubiquilin-2 | Ubiquitin-proteasome | X-linked; impairs proteasomal degradation |
| OPTN | Optineurin | Autophagy, NF-κB signaling | Direct substrate of TBK1 |
| CCNF | Cyclin F | Ubiquitin-proteasome | E3 ligase; mutations cause elevated K48-ubiquitylation and TDP-43 aggregation |
TBK1, optineurin, and p62 form a core genetic and functional network connecting autophagy with ALS-FTD pathogenesis.10
TDP-43 proteinopathy is the principal molecular bridge between ALS and FTD:2
TDP-43 pathology spreads in a sequential, predictable pattern in ALS:11
| Stage | Regions Affected |
|---|---|
| Stage 1 | Agranular motor cortex, brainstem motor nuclei (CN V, VII, X-XII), spinal cord alpha-motoneurons |
| Stage 2 | Prefrontal neocortex (middle frontal gyrus), brainstem reticular formation, precerebellar nuclei, red nucleus |
| Stage 3 | Prefrontal cortex (gyrus rectus, orbital gyri), postcentral neocortex, striatum |
| Stage 4 | Anteromedial temporal lobe, hippocampus |
Clinically diagnosed ALS-FTD patients correspond to Stage III or IV pathologically, reflecting spread from motor regions into frontotemporal cortices.
In C9orf72 expansion carriers, RAN translation from both sense and antisense transcripts generates five DPR species: poly-GA (most abundant), poly-GP (used as biomarker), poly-GR (highly toxic), poly-PA, and poly-PR (highly toxic). The arginine-containing DPRs impair nucleocytoplasmic transport, ribosomal function, and DNA repair.
The most established fluid biomarker for ALS-FTD. CSF NfL discriminates ALS from controls with 97% sensitivity and 95% specificity. Blood NfL levels predict survival (highest tertile: mortality HR 3.91). Elevated in both ALS and FTD, enabling scalable longitudinal monitoring.12
Recommended for all ALS patients regardless of family history per 2023 consensus guidelines. C9orf72 repeat-primed PCR and Southern blot; gene panels for ALS/FTD genes. Poly-GP DPR levels in CSF serve as pharmacodynamic biomarker for C9orf72-targeted therapies.13
There are currently no disease-modifying therapies for the ALS-FTD spectrum as a whole. FDA-approved ALS treatments include:
For FTD, there are no FDA-approved disease-modifying treatments.
Multidisciplinary care improves survival by up to 8 months:
Recommended for all ALS/FTD families, particularly with identified mutations. For C9orf72: 50% inheritance risk per child. Presymptomatic testing requires extensive counseling — a positive result does not predict whether disease will develop, age of onset, or phenotype.13
C9orf72-targeted ASOs: BIIB078 (tadnersen) and WVE-004 were both discontinued in Phase I/II after failing to show clinical benefit. Next-generation approaches are in development.15
Progranulin therapies: PR006 (AAV9 gene therapy, Phase 1/2) showed safety and increased CSF progranulin; VES001 (sortilin modulator) nearly doubled CSF progranulin levels.
TDP-43 targeting: AP-2 (Molefy Pharma) aims to restore TDP-43 balance; entering Phase 1.
The following resources provide additional data on genes and proteins related to Amyotrophic Lateral Sclerosis (ALS):
The study of Ftd Als Spectrum Disorder has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.